The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
Revolutionary ovarian cancer rapid test available Q4 2022
NWSS works with public health departments across the country to track SARS-CoV-2 levels in wastewater so communities can act quickly to prevent the spread of Covid-19.
Ahead of International Thalassemia Day on 8th May, medical professionals and representatives of patient bodies participated in a virtual discussion on the current situation of Thalassemia management in India
There is a need for the Ministry of Health to put it on the priority list and address the issues, which are numerous
Subscribe To Our Newsletter & Stay Updated
